Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Chen, LikunTrukhin, DmytroKolesnik, OleksiiDavid Gomez Rangel, Jose DavidCil, TimucinLi, XingyaCicin, IrfanKobziev, OlehShen, YihongLiu, ZhihuaOleksandr, IvashchukOzyilkan, OzgurIgor, BondarenkoUrsol, GrygoriiChen, JunOleksandr, KostiukChen, ZhendongZhang, HelongTural, DenizZhang, Li2022-11-042022-11-0420220732-183Xhttp://hdl.handle.net/11727/8007enginfo:eu-repo/semantics/closedAccessClinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.conferenceObject4016000863680302228